Preparation of thymus supernatant and application of thymus supernatant in immune cell culture
By using the newly born bovine thymus supernatant as an additive to the cell culture medium, the problems of low in vitro expansion efficiency of T cells and adverse reactions caused by fetal bovine serum in the prior art were solved, and efficient and safe T cells and hematopoietic stem cells were achieved. Amplification, suitable for clinical applications.
Patent Information
- Application Number
- CN202411171590.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-23
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2044-08-23
AI Technical Summary
Prior art When expanding T cells in vitro, it is difficult to obtain a sufficient number of active T cells in a short time, and the use of fetal bovine serum as a culture medium additive may lead to adverse reactions, limiting the application of T cells in immune cell therapy. .
Extracellular extracts (thymus supernatant) of newborn bovine thymus tissue are used as additives to cell culture medium. Cell components are removed by low-speed centrifugation and low-temperature treatment, and extracellular components such as cytokines are retained to enhance the in vitro expansion of T cells. Efficiency and tumor killing.
It significantly improves the in vitro expansion efficiency of T cells, maintains its typing diversity and tumor killing, and also has a highly efficient expansion effect in hematopoietic stem cell culture, reduces the apoptosis rate, and is suitable for large-scale production and clinical applications. .
Smart Images

Figure HDA0005009924230000011 
Figure HDA0005009924230000012 
Figure HDA0005009924230000013
Abstract
Description
Technical Field
[0001] The invention relates to a method for culturing immune cells and progenitor cells thereof, and in particular to the preparation of thymus supernatant and the application of the supernatant in culturing immune cells and progenitor cells thereof. Background Art
[0002] With the development and application of CAR-T cell therapy, T cell therapy has been widely used in the treatment of tumors, autoimmune diseases, etc. in recent years. In order to obtain T cells at the level of clinical application, it is generally necessary to separate T cells from umbilical cord blood (allogeneic) or peripheral blood (autologous) and then expand them in vitro. How to obtain a sufficient number of T cells in a short period of time and maintain their tumor-killing ability has always been the focus of in vitro expansion of T cells.
[0003] The current method for culturing T cells includes culturing T cells by serum-free medium or culturing T cells by fetal bovine serum or human serum as a medium additive. Among them, the advantage of using serum-free medium is that it belongs to non-animal origin, which reduces the risk of carrying animal-derived pathogens during cell in vitro expansion and reagent preparation, but the proliferation multiples of cultured T cells are limited and the number is small, so they cannot be widely used for treatment, which limits the application of T cells in immune cell therapy. The advantage of using fetal bovine serum or human serum as a medium additive to cultivate T cells is that fetal bovine serum (FBS) is easy to obtain and is widely used in the cultivation of T cells and other types of cells, but FBS-cultured T cells are prone to adverse reactions in clinical experiments. Therefore, it has become a demand to find a composition or method that can efficiently amplify T cells and their progenitor cells in vitro.
[0004] The thymus of mammals is the place where T cells develop and mature. The thymus of mammals is the first organ to begin aging after birth. In the aged thymus, fibroblasts and adipocytes will multiply, while the microenvironment that supports the development of T cells will gradually be lost. Therefore, it is closely related to the growth and development of T cells.
[0005] At present, the research on thymus tissue promoting T cell proliferation and development mainly focuses on the research of thymosin, in which the thymosin is mainly a polypeptide component extracted by breaking the cells, which belongs to intracellular polypeptide. For example, patent CN100402085C describes "the extraction method of thymosin solution is: take fresh or quick-frozen thymus, remove impurities and wash; add water to the treated thymus to prepare a homogenate; freeze and thaw the homogenate repeatedly; heat the freeze-thaw solution to remove unstable impurities, and then centrifuge and filter to obtain the supernatant; ultrafiltration of the supernatant to retain components with a molecular weight of less than 10,000 Daltons to obtain a low-concentration thymosin solution." From the above extraction method, it can be seen that the extraction technology of thymosin will completely break up the thymus cells and completely release the cell contents. Regarding the use of thymosin in immune cell culture, patent CN115247148B introduces thymopentin as an additive to immune cell culture medium.
[0006] However, there are few studies on thymic supernatant (whose main component is thymic extracellular substances) and its application. Summary of the invention
[0007] In one aspect of the present invention, a method for culturing or expanding immune cells or progenitor cells thereof in vitro is provided, which comprises adding an extracellular extract of thymus tissue to a cell culture medium.
[0008] In a specific embodiment of the present invention, the immune cells or their progenitor cells include T cells, B cells, NK cells, NKT cells, macrophages, TIL cells, CIK cells, TCR-T cells and other tumor killer cells, and hematopoietic stem cells.
[0009] In a specific embodiment of the present invention, the thymus tissue is obtained from a mammal, preferably a newborn mammal; optionally, the mammal comprises cattle, sheep, horses, pigs, preferably cattle.
[0010] At present, the culture medium for T cell expansion on the market is generally divided into serum culture medium and serum-free culture medium, on which the cytokines necessary for T cell expansion (IL2, IL7, IL15, etc.) are added. The present invention first screens the commonly used culture systems on the market to determine the optimal T cell culture conditions to verify the subsequent addition of thymic tissue extracellular extracts, including the screening of basal culture medium and cytokines, for example, three serum-containing culture media (1640+FBS, 1640+βME+FBS, αMEM), two serum-free culture media (X-VIVO15, ImmunoCult-XF), and various cytokine combinations. The in vitro expansion rate of T cells; ultimately determined to be ImmunoCult-XF+IL7 / IL15. It should be noted that the present invention only exemplary screens the above culture conditions, and those skilled in the art can understand that the above culture conditions are only exemplary optimal conditions, and the culture conditions conventionally used for immune cells such as T cells in the prior art can be applied to the present invention, that is, the thymic tissue extracellular extract of the present invention can be applied to any conventional cell culture conditions in the prior art.
[0011] In order to create a microenvironment that is more conducive to the expansion and differentiation of immune cells such as T cells and immune cell progenitor cells in vitro expansion, the present invention adds the extracellular extract of thymus tissue of the present invention (also known as newborn bovine thymus extract, Newborn bovine THYmic supernatant, THY) on the basis of the existing culture system currently on the market. Compared with thymic peptides in the prior art or fetal bovine serum conventionally used for T cell culture in the prior art, it can obtain more numbers of immune cells (such as T cells) and immune cell progenitor cells (such as hematopoietic stem cells; HSC) in a short time. Specifically, it improves the in vitro expansion efficiency of T cells, maintains its typing diversity, and enhances the tumor killing of T cells. In addition, it is applied to the hematopoietic stem cell (immune cell progenitor cell group) culture system to efficiently expand hematopoietic stem cells.
[0012] In another aspect, the present invention provides a cell culture medium comprising an extracellular extract of thymus tissue.
[0013] Among them, the thymus tissue extracellular extract is also called thymus supernatant, which is used as a T cell culture additive, and its effect is better than the existing market expansion system. It not only improves the in vitro expansion efficiency of T cells, but also enhances the tumor killing ability of T cells. In addition, it is applied to the hematopoietic stem cell (immune cell progenitor cell group) culture system to efficiently expand hematopoietic stem cells.
[0014] The thymus supernatant THY is different from the thymus tissue extract in the prior art (such as thymosin, which is mainly an intracellular polypeptide). The components of the thymus supernatant of the present invention are mainly extracellular components such as cytokines. The inventors analyzed the components of the thymus supernatant THY and compared it with the components of fetal bovine serum FBS traditionally used as a cell culture additive, and found that it contains a variety of common cytokines in fetal bovine serum FBS, such as IL7, IL2, IL15, IL12, TNFα, INFγ, GM-CSF. And under the same total protein concentration, the content of these cytokines is much higher than that of fetal bovine serum.
[0015] In a specific embodiment of the present invention, an extracellular extract from bovine thymus tissue is exemplarily provided. Those skilled in the art can expect that extracellular extracts from thymus tissues of other mammals also have the same effect.
[0016] The extract of the present invention first removes cell components by low-speed centrifugation (600-4000 rpm, preferably 800-3000 rpm), so that the extracellular active ingredients of thymocytes are highly enriched, and the cytokines related to the expansion and activation of immune cells are mainly secretory polypeptides. Therefore, compared with the existing thymosin preparation solution, the concentration of the active ingredients supporting the expansion of immune cells is greatly improved. Second, the whole process is operated at low temperature (2-10°C, preferably 4-6°C), which retains the spatial active structure of the active ingredients.
[0017] Furthermore, the present invention proves through comparative experiments that the thymus supernatant extract as a cell culture additive has a stronger amplification effect on immune cells than thymopentin or fetal bovine serum conventionally used for cell culture in the prior art.
[0018] In a specific embodiment of the present invention, the content of the thymus supernatant extract in the cell culture medium can be routinely adjusted as needed, such as 5%-20% or 5%-15% by volume, such as 10% by volume.
[0019] The cell culture medium further comprises cytokines known in the prior art for T cell culture, such as IL7 and IL15; preferably, the content of IL7 and IL15 is 5-15 ng / ml, such as 10 ng / ml.
[0020] Alternatively, the cell culture medium further comprises growth factors known in the prior art for maintaining stem cell proliferation, such as 5-15 ng / ml SCF, 80-120 ng / ml TPO, 80-120 ng / ml FILT3; preferably 10 ng / ml SCF, 100 ng / ml TPO, 100 ng / ml FILT3.
[0021] On the other hand, the present invention also provides a method for preparing the thymus tissue extracellular extract, which comprises adding a buffer to the thymus tissue to dissolve the thymus tissue extracellular substances in the buffer, and collecting the supernatant by centrifugation.
[0022] The centrifugation includes firstly low-temperature low-speed centrifugation to remove cell components, and then low-temperature high-speed centrifugation to remove cell debris;
[0023] In a specific embodiment of the present invention, the buffer solution is a conventional physiological buffer solution in the prior art, such as PBS phosphate buffer solution, Hank's balanced salt solution; the amount of the buffer solution added can be conventionally selected, for example, 300 ml of buffer solution is added per 100 g of thymus tissue.
[0024] In a specific embodiment of the present invention, the low-temperature low-speed centrifugation is 600-4000 rpm, preferably 800-3000 rpm, 2-10°C, preferably 2-8°C, more preferably 4-6°C for centrifugation for 5-15 minutes; the low-temperature high-speed centrifugation is 6000-12000 rpm, 2-10°C, preferably 2-8°C, more preferably 4-6°C for centrifugation for 20-40 minutes.
[0025] In a specific embodiment of the present invention, the process further comprises removing pollutants from the supernatant; preferably, the pollutants from the supernatant are removed by membrane filtration to obtain a purified thymus tissue extracellular extract (also called thymus supernatant).
[0026] In a specific embodiment of the present invention, the purpose of the membrane filtration treatment is to remove pollutants such as bacteria and mycoplasma, and pollutants can also be removed by ultraviolet irradiation, radiation sterilization, activated carbon adsorption and other methods.
[0027] Compared with the preparation methods of thymic tissue extracts in the prior art, the thymic supernatant preparation method of the present invention is simple to operate. For example, (1) the preparation of thymic tissue extracts in the prior art usually requires cell disruption, that is, the cells are completely disrupted by a trypsin digestion step to release the internal contents of the cells, while the preparation method of the present invention does not require cell disruption, and retains extracellular substances to the maximum extent, which is better used to support the supplementation of nutrients during in vitro cell expansion. (2) The preparation method of the present invention reduces the high-temperature cooking step. The high-temperature treatment used in the preparation method of thymic extracts in the prior art will inactivate most of the proteins. The present invention maintains low temperature throughout the process, which greatly protects the activity of effective proteins.
[0028] In the present invention, the mammal is selected from humans, mice, rats, dogs, cats, rabbits, pigs, monkeys, horses, cattle or sheep; in a preferred embodiment of the present invention, the newborn mammal refers to a newborn calf, and the newborn calf refers to a cattle within 30 days of birth, preferably within 24 hours, preferably within 14 hours of birth and without food.
[0029] In another aspect of the present invention, provided are immune cells or progenitor cells thereof obtained by the above method, and preparations containing the immune cells or progenitor cells thereof.
[0030] In a specific embodiment of the present invention, the preparation further comprises a pharmaceutically acceptable excipient.
[0031] In a specific embodiment of the present invention, the pharmaceutically acceptable adjuvant refers to a diluent, adjuvant or excipient used with the preparation of the present invention or the cell, including saline, gum arabic, gelatin, starch paste, talcum powder, keratin, colloidal silicon dioxide, urea, etc. In addition, adjuvants, stabilizers, thickeners, lubricants and coloring agents can be used. In one embodiment, when applied to animals, the pharmaceutically acceptable adjuvant is sterile. When intravenously administered, water is a preferred adjuvant. Saline solutions and aqueous glucose solutions and glycerol solutions can also be used as liquid adjuvants, particularly for injection solutions.
[0032] In another aspect of the present invention, provided is the use of immune cells or their progenitor cells or the preparation in the preparation of a medicament for treating a tumor; in a specific embodiment of the present invention, the tumor includes a solid tumor or a non-solid tumor.
[0033] In a specific embodiment of the invention, the tumor can be selected from bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular cancer, breast cancer, brain cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, esophageal cancer, small intestine cancer, cancer of the endocrine system, thyroid cancer, parathyroid cancer, adrenal cancer, kidney cancer, soft tissue sarcoma, urethral cancer, bladder cancer, renal cancer, lung cancer, non-small cell lung cancer, thymoma, prostate cancer, mesothelioma, adrenocortical carcinoma, lymphoma, for example Hodgkin's disease, non-Hodgkin's disease, gastric cancer, leukemias such as ALL, CLL, AML, urothelial leukemia and multiple myeloma.
[0034] In one embodiment, the tumor is a solid tumor. Examples of solid tumors that can be treated accordingly include breast cancer, lung cancer, colorectal cancer, pancreatic cancer, gliomas, and lymphomas. Some examples of such tumors include epidermoid tumors, squamous tumors, such as head and neck tumors, colorectal tumors, prostate tumors, breast tumors, lung tumors, including small cell and non-small cell lung tumors, pancreatic tumors, thyroid tumors, ovarian tumors, and liver tumors. Other examples include Kaposi's sarcoma, CNS, neoplasms, neuroblastomas, capillary hemangioblastomas, meningiomas and brain metastases, melanomas, gastrointestinal and renal cancers and sarcomas, rhabdomyosarcomas, glioblastomas, preferably glioblastoma multiforme and leiomyosarcomas. Examples of vascularized skin cancers for which the antagonists of the present invention are effective include squamous cell carcinomas, basal cell carcinomas, and skin cancers that can be treated by inhibiting the growth of malignant keratinocytes, such as human malignant keratinocytes.
[0035] In one embodiment, the tumor is a non-solid tumor. Examples of non-solid tumors include leukemia, multiple myeloma, and lymphoma.
[0036] Specifically, the present invention provides the following technical solutions:
[0037] 1. A method for culturing or expanding immune cells or progenitor cells thereof in vitro, comprising adding an extracellular extract of thymus tissue to a cell culture medium.
[0038] 2. The method according to item 1, wherein the immune cells or their progenitor cells include T cells, B cells, NK cells, NKT cells, macrophages, TIL cells, CIK cells, TCR-T cells and other tumor-killing cells, and hematopoietic stem cells.
[0039] 3. The method according to item 1 or 2, wherein the thymus tissue is obtained from a mammal, preferably a newborn mammal; optionally, the mammal comprises cattle, sheep, horses, pigs, preferably cattle.
[0040] 4. The method according to item 1 or 2, wherein the cell culture medium further comprises IL7 and IL15; preferably, the concentrations of IL7 and IL15 are 5-15 ng / ml, more preferably 8-12 ng / ml, respectively;
[0041] Preferably, the basal medium of the cell culture medium is 1640 medium, 1640+β-ME medium, αMEM medium, Lonza X-vivo15 medium or ImmunoCult-XF medium; preferably ImmunoCult-XF medium.
[0042] 5. The method according to item 1 or 2, wherein the cell culture medium further comprises 5-15 ng / ml SCF, 80-120 ng / ml TPO, and 80-120 ng / ml FILT3; preferably, the basal culture medium of the cell culture medium is IMDM culture medium.
[0043] 6. An immune cell or a progenitor cell thereof obtained by the method according to any one of items 1 to 5.
[0044] 7. A cell culture medium comprising an extracellular extract of thymus tissue; preferably, the content of the extracellular extract of thymus tissue is 5%-20% by volume.
[0045] 8. The cell culture medium according to item 7, further comprising IL7 and IL15; preferably, the concentrations of IL7 and IL15 are 5-15 ng / ml, more preferably 8-12 ng / ml, respectively;
[0046] Preferably, the basal medium of the cell culture medium is 1640 medium, 1640+β-ME medium, αMEM medium, Lonza X-vivo15 medium or ImmunoCult-XF medium; preferably ImmunoCult-XF medium.
[0047] 9. The cell culture medium according to item 7, further comprising 5-15 ng / ml SCF, 80-120 ng / ml TPO, 80-120 ng / ml FILT3; preferably, the basal medium of the cell culture medium is IMDM medium.
[0048] 10. Use of an extracellular extract of thymus tissue or a cell culture medium according to any one of items 7 to 9 for culturing or expanding immune cells or progenitor cells thereof in vitro.
[0049] 11. A method for preparing an extracellular extract of thymus tissue, comprising adding a buffer to the thymus tissue to dissolve the extracellular substances of the thymus tissue in the buffer, and collecting the supernatant by centrifugation.
[0050] 12. The preparation method according to item 11, wherein the centrifugation comprises first low-temperature low-speed centrifugation and then low-temperature high-speed centrifugation;
[0051] Optionally, the low-temperature low-speed centrifugation is 600-4000 rpm, preferably 800-3000 rpm, at 2-10°C, preferably 2-8°C, more preferably 4-6°C, for 5-15 minutes; optionally, the low-temperature high-speed centrifugation is 6000-12000 rpm, at 2-10°C, preferably 2-8°C, more preferably 4-6°C, for 20-40 minutes.
[0052] 13. A preparation comprising the immune cells or progenitor cells thereof as described in item 6; optionally, the preparation further comprises a pharmaceutically acceptable excipient.
[0053] 14. Use of the immune cells or their progenitor cells described in Item 6 or the preparation described in Item 13 in the preparation of a drug for treating a tumor; optionally, the tumor includes a solid tumor or a non-solid tumor.
[0054] Technical effect:
[0055] 1. The present invention provides a newborn animal thymus supernatant and a method for separating and purifying the same: the present invention can extract a supernatant having a variety of active ingredients from the thymus of newborn mammals, which retains the macromolecular proteins and exosome vesicles naturally present in the thymus of young animals, as well as other non-protein active ingredients, and removes other impurities, bacteria and mycoplasma to meet the needs of cell culture.
[0056] 2. Compared with the prior art, the present invention uses THY as an additive for T cell culture. T cells can not only be rapidly expanded in a short period of time, but the expanded T cells also have stronger tumor killing performance.
[0057] 3. The present invention uses animal-derived thymus supernatant to culture T cells, which is easier to obtain and suitable for large-scale production and application. In view of the fact that the T cells amplified by the present invention have been widely used in the treatment of various tumors, the THY prepared by the present invention has good application prospects and market value. BRIEF DESCRIPTION OF THE DRAWINGS
[0058] Figure 1 A flow chart for the preparation of newborn calf thymus supernatant is shown;
[0059] Figure 2 The results of quantitative analysis of cytokines contained in the supernatant of newborn calf thymus THY are shown;
[0060] Figure 3 The effect of newborn calf thymus supernatant THY on the morphology of T cell expansion in vitro is shown;
[0061] Figure 4 The effect of newborn calf thymus supernatant THY on the cell multiplier of T cell expansion in vitro is shown;
[0062] Figure 5 The effect of newborn calf thymus supernatant THY on T cell apoptosis was shown;
[0063] Figure 6 The effect of newborn calf thymus supernatant THY on T cell expansion and typing in vitro was shown;
[0064] Figure 7It shows the killing effect of T cells cultured with newborn calf thymus supernatant THY on lung cancer cells A549;
[0065] Figure 8 It shows the killing effect of T cells cultured with newborn calf thymus supernatant THY on the hematological tumor cell line NALM6;
[0066] Fig. 9 It was shown that newborn calf thymus supernatant THY promoted T cell CD107a degranulation;
[0067] Fig.10 It was shown that newborn calf thymus supernatant THY promoted T cell perforin secretion;
[0068] Fig.11 It shows that T cells amplified by THY from the supernatant of newborn calf thymus prolong the survival of mice; wherein, A represents the animal experiment model diagram; B represents the survival curve diagram of mice in each group after THY-amplified peripheral blood-derived T cells are injected into the tumor mouse model; C represents the survival curve diagram of mice in each group after THY-amplified umbilical cord blood-derived T cells are injected into the tumor mouse model;
[0069] Fig.12 It shows that T cells amplified by THY in the supernatant of newborn calf thymus slow down the progression of tumor development; wherein, A represents the image of the size of residual tumor foci in mice on the 7th day, the 14th day, the 21st day, and the 28th day after THY-amplified peripheral blood-derived T cells PBMCT were injected into the tumor mouse model; B represents the image of the size of residual tumor foci in mice on the 7th day, the 18th day, the 28th day, and the 39th day after THY-amplified umbilical cord blood-derived T cells UBMCT were injected into the tumor mouse model;
[0070] Fig.13 The effect of newborn calf thymus supernatant THY on the number of hematopoietic stem cells expanded in vitro was shown;
[0071] Fig.14 The effect of calf thymus supernatant THY on the colony-forming ability of hematopoietic stem cells is shown.
[0072] Fig.15 The results show that the supernatant of newborn calf thymus THY has a stronger expansion effect on T cells than thymopentin, thymosin α and thymosin β4 in the prior art.
[0073] Fig.16 The results of screening of T cell in vitro expansion medium are shown. A shows the expansion of PBMC T cells after 7 days of culture in three different serum-containing mediums; B shows the expansion of T cells after 7 days of culture in αMEM medium and two other serum-free mediums; C shows the comparison of T cell expansion speed under various cytokine combinations. DETAILED DESCRIPTION
[0074] In order to make the objectives, technical solutions and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with specific embodiments and with reference to the accompanying drawings.
[0075] The methods used in the following examples are conventional methods unless otherwise specified, and the reagents used are commercially available reagents unless otherwise specified.
[0076] Example 1 A method for extracting calf thymus supernatant. The steps include:
[0077] 1. Preparation of buffer solution: Use a sterile physiological buffer solution, such as PBS phosphate buffer solution, Hank's balanced salt solution, etc. Preferably, add 200 IU / mL heparin sodium anticoagulant to the above buffer solution, and add protease inhibitors at a volume ratio of 1 / 100 to inhibit protein degradation. Stir the buffer solution evenly and store it on ice.
[0078] 2. Obtaining thymus tissue from newborn calves. Take thymus tissue from newborn calves (including yellow cattle, dairy cows, Angus cattle, regardless of gender), rinse it with physiological saline, and place it in a sterile tray.
[0079] 3. Use surgical scissors sterilized with high temperature to remove and discard the fascia and excess fat on the surface of the thymus tissue, and cut the remaining part into small pieces of about 2 mm. Add the prepared pre-cooled buffer solution to dissolve and release the thymus fluid contents in the buffer solution. Preferably, add the buffer solution according to a certain volume ratio, for example: add 300 ml of pre-cooled buffer solution for every 100 g of thymus tissue. After fully stirring, place it on ice for 10-30 minutes to soak, so that the thymus contents are released and dissolved in the buffer solution.
[0080] 4. Transfer the buffer solution containing the thymus contents into sterile 50 ml centrifuge tubes and use a centrifuge to remove the cell tissue precipitate. Specifically, centrifuge at 2000 rpm and 4°C for 10 minutes to collect the supernatant; further centrifuge the supernatant at 10000 rpm and 4°C for 30 minutes. Transfer the supernatant to a new sterile container.
[0081] 5. Under aseptic conditions, the mixture solution is filtered to remove contaminants such as bacteria and mycoplasma. The sterilization methods include but are not limited to ultraviolet irradiation, radiation sterilization, activated carbon adsorption, membrane filtration, etc. Preferably, the mixture is filtered once with a 0.45 μm filter membrane and a 0.22 μm filter membrane, and the supernatant is filtered three times with a 0.1 μm filter membrane, and the extract is stored at -80°C.
[0082] 6. The supernatant obtained above is thymus supernatant (THY), which can be used for subsequent cell culture and other applications. Figure 1 shown.
[0083] Furthermore, the present invention also changes the centrifugation conditions, which can also obtain thymic supernatant (THY), and the thymic supernatant (THY) can still achieve the technical effects of the present invention. For example, first centrifuge at 600 rpm and 2°C for 15 minutes to collect the supernatant; then the obtained supernatant is further centrifuged at 12,000 rpm and 2°C for 20 minutes to obtain thymic supernatant THY; or, first centrifuge at 4,000 rpm and 10°C for 5 minutes to collect the supernatant; then the obtained supernatant is further centrifuged at 6,000 rpm and 2°C for 40 minutes to obtain thymic supernatant THY.
[0084] Example 2: Quantitative analysis results of cytokines contained in calf thymus supernatant THY.
[0085] The calf thymus supernatant THY obtained in Example 1 was mixed with fetal bovine serum FBS (#10091148; Gibco TM ) Cytokine determination was performed by enzyme-linked immunosorbent assay. Figure 2 As shown, a variety of common cytokines in fetal bovine serum FBS can be detected in the above-mentioned newborn calf thymus supernatant THY, including IL7, IL2, IL15, IL12, TNFα, INFγ, and GM-CSF. And under the same total protein concentration, the content of these cytokines is much higher than that of fetal bovine serum. Given that these cytokines regulate cell proliferation for immune cells (such as T cells, NK cells, DC cells, macrophages), and also play an important role in maintaining the characteristics of hematopoietic stem cells, the experimental results show that the newborn calf thymus supernatant THY prepared by the above method contains a large number of active ingredients.
[0086] Example 3: Effect of calf thymus supernatant THY on the morphology of T cell expansion in vitro
[0087] The T cells used in the present invention have two sources, one is the peripheral blood of healthy volunteers, named PBMCT; the other is the umbilical cord blood of healthy pregnant volunteers, named UBMCT. Both T cell extraction and preparation methods use CD3 microbeads (#130-097-043; Miltenyi Biotec), and the extraction is performed according to the reagent instructions. After enrichment, the T cells are inoculated in T25 culture flasks, and the starting cell number in each flask is 1X10 5The growth of T cells in the experimental group and the control group was compared. The cell morphology and size were observed under a microscope to reflect the cell activity status.
[0088] Before the experiment, we conducted preliminary experiments on the T cell expansion medium currently on the market to determine the optimal culture conditions. T cell expansion medium is generally a basic medium supplemented with growth factors necessary for expansion. Fig.16 A shows the expansion of PBMC T cells after 7 days of culture in three different serum-containing culture media (1640 medium, 1640+β-ME medium and αMEM medium). The results show that T cells expand faster under αMEM basic medium conditions. Fig.16 B shows the T cell expansion after 7 days of culture in αMEM medium and two other serum-free mediums (Lonza X-vivo15 medium and ImmunoCult-XF medium) in the above results. The results show that the serum-free medium ImmunoCult-XF condition makes T cells expand faster. Fig.16 C is a comparison of T cell expansion rates under various cytokine combinations (IL2, IL12, IL2 / IL12, IL7 / IL12, IL15 / IL12 and IL7 / IL15; concentration: 10 ng / ml). The results show that the T cell expansion rate is the fastest under the IL7 / IL15 combination. Therefore, in the following implementation plan experiment, the basic culture medium is selected as ImmunoCult-XF culture medium, and the cytokine condition is 10 ng / ml IL7 / IL15.
[0089] In this embodiment, the steps for culturing T cells include: the experimental group "THY" medium composition is ImmunoCult-XF medium (#10981; STEMCELL Technology), 10ng / mL IL7 / IL15, 10% volume ratio of the above-mentioned newborn calf thymus supernatant THY, and Dynabeads are added to this medium every three days. TM Human T-Activator CD3 / CD28 magnetic beads (#11132D; Thermo Fisher) were used as T cell activators; the control group "PBS" medium composition was ImmunoCult-XF medium (#10981; STEMCELL Technology), 10 ng / mL IL7 / IL15, 10% PBS buffer by volume; on this basis, Dynabeads were added every three days TMHuman T-Activator CD3 / CD28 magnetic beads (#11132D; Thermo Fisher) were used as T cell activators. Zeiss Axio Observer 7 inverted microscope was used to take pictures and record the cell morphology and number on Day 0, Day 1, Day 3, Day 5, Day 7, Day 9, Day 11 and Day 14 of culture. Observe the results of Day 7 microscope photography ( Figure 3 ) It can be seen that both the control group and the experimental group cells showed multiple densely growing cell clusters and scattered single cells around them. The normal clustering of T cells is extremely important for the in vitro expansion and activity maintenance of T cells. Therefore, the T cells treated with THY still maintained the basic morphology of PBMCT cells and the colony characteristics of clustered growth.
[0090] Example 4: Effect of calf thymus supernatant THY on T cell proliferation in vitro
[0091] In this example, the effect of THY on the cell multiplier of T cell expansion in vitro was studied. The control group "PBS" culture medium composition was ImmunoCult-XF culture medium (#10981; STEMCELL Technology), 10ng / mL IL7 / IL15, volume ratio 10% PBS buffer; on the basis of this culture medium, Dynabeads were added every three days TM Human T-ActivatorCD3 / CD28 magnetic beads (#11132D; Thermo Fisher) were used as T cell activators. The experimental group "THY" culture medium composition was ImmunoCult-XF culture medium (#10981; STEMCELL Technology), 10ng / mL IL7 / IL15, 10% volume ratio of the above-mentioned newborn calf thymus supernatant THY, and Dynabeads were added every three days on the basis of this culture medium TM Human T-ActivatorCD3 / CD28 magnetic beads (#11132D; Thermo Fisher) were used as T cell activators. On Day 0, Day 1, Day 3, Day 5, Day 7, Day 9, Day 11, and Day 14 after culture, the total number of cells was counted and recorded using a countstar cell analyzer, and the cell expansion multiples were analyzed and plotted. ** represents a p-value less than 0.01.
[0092] Figure 4It can be seen that under the culture conditions of the control group, after 14 days of in vitro expansion, T cells derived from peripheral blood can be expanded 37 times, and T cells derived from umbilical cord blood can be expanded 151 times in the same time period. Under THY culture conditions, T cells derived from peripheral blood expanded 89 times in two weeks, and T cells derived from umbilical cord blood expanded 558 times. The results show that the addition of the thymus supernatant of the present invention can effectively increase the efficiency of T cell in vitro expansion compared to the control group. Therefore, the addition of the thymus extract of newborn animals involved in the present invention can greatly improve the efficiency of T cell in vitro expansion.
[0093] Example 5: Effect of calf thymus supernatant THY on T cell apoptosis
[0094] In this example, the effect of THY on T cell apoptosis was studied. Among them, using 7AAD and Annexin V-PE channels to detect apoptosis in cell in vitro expansion is a common method in the prior art. When the flow cytometry results were analyzed, normal cells showed double negativity in both 7AAD and Annexin V channels, while early apoptotic cells showed single positivity in Annexin V and negative 7-AAD, and late apoptotic cells were indicated by double positivity in 7AAD and Annexin V. After culturing the experimental group and the control group (wherein, the culture conditions of the experimental group and the control group refer to Examples 3 and 4 above) for 7 days, the cells were collected, centrifuged at 300g for 5 minutes, and the supernatant was removed. The cells were resuspended in complete culture medium and counted, and 5X10 5 The cells were resuspended to 100 μl. According to the conventional flow cytometry operation method, a blank control group was set up to adjust the instrument voltage, an antibody single staining group was used to adjust the compensation, and an FMO control group was used to determine the accuracy of the gate and the experimental group. First, 5 μl of blocked Fc receptor (#130-059-901; Miltenyi Biotec) was added to reduce nonspecific binding during the staining process, and then the corresponding antibody (#559763; BD Pharmingen) was added and mixed well, and then placed in a 4-degree refrigerator away from light for 30 minutes. At the end of the incubation, 500 ul of staining buffer was added to resuspend the cells, centrifuged at 300 g for 5 minutes, and the supernatant was discarded. Finally, the cells were resuspended with 200 μl of staining buffer, detected with a Beckman CytoFLEX S flow cytometer, and analyzed with FlowJO software.
[0095] from Figure 5 The results of flow cytometry analysis showed that the premature apoptosis rate of T cells cultured under the conditions of newborn calf thymus supernatant THY decreased from 13.6% in the control group to 5.38%. The late apoptotic cells also decreased from 0.51% in the control group to 0.18%. Therefore, newborn calf thymus supernatant THY can greatly reduce the apoptosis rate of T cells during culture.
[0096] Example 6: Effect of calf thymus supernatant THY on T cell expansion and typing in vitro
[0097] T cells are a heterogeneous cell population. According to their linear differentiation relationship, T cells can be divided into naive To stem cell memory (Stem Cell Memory, SCM), central memory (Central Memory, CM), effector memory (Effector Memory, EM), and finally to the terminal effector (Terminal Effector, TE, or also known as EMRA) stage. Among them, central memory T cells (TCM) are differentiated from immature T cells after encountering specific antigens and receiving appropriate co-stimulatory signals. Generally speaking, TCM has a smaller proportion in childhood, but with the increase of age and the atrophy of the thymus, it maintains a growing trend and maintains a relatively stable proportion. Effector memory T cells (TEM) are also differentiated from immature T cells. However, compared with central memory T cells, effector memory T cells have stronger immediate effect functions, can quickly produce cytokines and cytotoxic effects, but have lower proliferation and lymph homing potential. In this example, the experimental group and the control group (wherein, the culture conditions of the experimental group and the control group refer to the above examples 3 and 4) were cultured for 7 days, and then the cells were collected, centrifuged at 300g for 5min, and the supernatant was removed. The cells were resuspended in complete culture medium and counted, and 5X10 5 The cells were resuspended to 100ul. According to the conventional flow cytometry operation method, a blank control group was set up to adjust the instrument voltage, an antibody single staining group was used to adjust the compensation, and an FMO control group was used to determine the accuracy of the gate and the experimental group. First, 5μl of blocked Fc receptor (#130-059-901; Miltenyi Biotec) was added to reduce nonspecific binding during the staining process, and then the corresponding antibody was added and mixed and placed in a 4-degree refrigerator away from light for 30 minutes. At the end of the incubation, 500ul of staining buffer was added to resuspend the cells, centrifuged at 300g for 5 minutes, and the supernatant was discarded. Finally, the cells were resuspended with 200ul of staining buffer, detected with a Beckman CytoFLEX S flow cytometer, and finally analyzed with FlowJO software. The antibody information used is: CD4-PerCP (#300528; Biolegend), CD8-BV510 (#344732; Biolegend), CCR7-BV421 (#353208; Biolegend) CD45RA-PECY7 (#560675; BD Pharmingen).
[0098] from Figure 6It can be seen that THY did not change the proportion of CD4+T cells and CD8+T cells during in vitro expansion. At the same time, the differentiation diversity of TN (T naive), TE (T effector), TEM (effector memory T cells, TEM) and TCM (central memory T cells, TCM) was maintained; for example, compared with the control group, the diversity of TEM (effectormemory T cells, TEM) and TCM (central memory T cells, TCM) and TN (T naive) typing was maintained.
[0099] Example 7: Cytotoxicity of T cells cultured with calf thymus supernatant THY on lung cancer cells A549
[0100] T cells are the main force of the immune system to kill tumor cells and are one of the key points in the study of heterogeneity of immunotherapy. T cell immune response is completed through TCR. When the body is stimulated by antigens, TCR interacts with MHC-presented antigen complexes to produce effector lymphocytes that can cross tissues and eliminate target antigens, as well as memory cells that can persist and provide long-term protection in the event of another antigen attack. Each T cell has a unique TCR molecule on its surface.
[0101] In order to verify the killing effect of T cells amplified by THY on tumors, this example selected lung cancer A549 cells (#CL-0016; Procell / Punosai) with mCherry fluorescent label as tumor killing objects. A549 cells (5×10 5 cells) and T cells (5X10 5 cells / group) co-cultured (effect-target ratio 1:1), (wherein, the culture conditions of the experimental group and the control group refer to the above Examples 3 and 4) After 24 hours, the mixed cells were collected, and the T cells were labeled with CD3 antibody (#557832; BD Pharmingen) through the Apccy7 channel, and the A549 tumor cells were labeled with the mCherry channel. The detection was performed using a Beckman CytoFLEX S flow cytometer, and finally analyzed using FlowJO software.
[0102] The results are as follows Figure 7 As shown in the left figure, after 24 hours of in vitro co-culture, the survival rate of A549 in the control group was still 29% compared to the initial cell amount, while after the T cells in the THY-treated group were co-cultured with A549, the survival rate of tumor cells was only 7.14%. The experiment was repeated three times and the statistics were calculated. The results are as follows Figure 7As shown in the right figure, THY-cultured T cells have a significant killing effect on tumor cells A549 compared with the control group.
[0103] Example 8: Cytotoxic effect of T cells cultured with calf thymus supernatant THY on hematological tumor cell line NALM6
[0104] In order to further verify the killing effect of T cells amplified by THY on tumors, this example selected another human B lymphocyte leukemia tumor cell line NALM6 (#CL-0701; Procell / Punosai) with mCherry fluorescent label as the killing target. Similarly, NALM6 cells (5×10 5 cells) and the experimental group and control group (wherein, the culture conditions of the experimental group and the control group refer to the above Examples 3 and 4) obtained after 14 days of in vitro expansion (5×10 5 cells / group) co-cultured (effect-target ratio 1:1), after 24 hours, the mixed cells were collected, and T cells were labeled with CD3 antibody (#557832; BD Pharmingen) in the Apccy7 channel, and NALM6 tumor cells were labeled with mCherry channel. Beckman CytoFLEX S flow cytometer was used for detection, and finally FlowJO software was used for analysis.
[0105] Flow cytometry results ( Figure 8 Left) It can be observed that after T cells cultured with calf thymus supernatant THY were co-cultured with NALM6, the survival rate of NALM6 cells was lower (18.52% in the experimental group vs. 73.4% in the control group). The experiment was repeated three times and the results were statistically analyzed. Figure 8 As shown in the right figure, T cells cultured with newborn calf thymus supernatant THY have a stronger killing effect on tumor cells NALM6 than the control group.
[0106] Example 9: Calf thymus supernatant THY promotes T cell CD107a degranulation
[0107] Perforin and granzyme are two important molecules involved in the killing of tumor cells by cytotoxic T cells. After recognizing tumor cells, cytotoxic T cells release perforin, which forms pores on the target cell membrane, allowing granzymes to enter the cell, thereby inducing apoptosis of tumor cells. When cytotoxic T cells kill target cells, toxic granules will reach the cell membrane and fuse with the cell membrane. At this time, lysosome-associated membrane protein-1 (CD107a molecule) is transported to the cell membrane surface, causing the release of granule contents, ultimately leading to the death of target cells. Therefore, the CD107a molecule is a marker for cytotoxic T cell degranulation, and its expression level is significantly correlated with the killing activity of T cells.
[0108] This example uses NALM6 cells (#CL-0701; Procell / Pnocell), and the culture medium is supplemented with 10% FBS (#10091148; Gibco TM ) in DMEM medium. Set up T cell killing experiment: adjust the concentration of NALM6 cells to 10 6 The T cell concentration obtained after 14 days of in vitro expansion was adjusted to 5X10 6 Cells / mL, the effect-target ratio (E:T) is 5:1. The experiment is divided into four groups: basic degranulation level group (100μl PBMC-T+100μl DMEM culture medium), control group (100μl PBS-T+100ul NALM6 cells), experimental group (100μl THY-T+100μl NALM6 cells), positive control group (100μl PBMC-T+100ul DMEM culture medium containing 100ng / mL PMA and 2μg / mL ionomycin). Among them, the culture conditions of THY-T and PBS-T refer to the above-mentioned Examples 3 and 4, and the PBMC-T culture conditions are the same as the PBS-T cell culture conditions. Among them, PMA / ionomycin are the two most common cell stimulants, which are used as positive controls to stimulate the activation of T cells. According to the settings of the four groups, they are added to a 96-well U-shaped plate, so that each well has a total volume of 200μl. Next, 10 μL of anti-human CD107a antibody (#560664; BD Pharmingen) was added to each well and incubated at 37°C and 5% CO2 for 4 hours. During the 1-hour incubation, 2 ul of monensin was added to block the expression of CD107a molecules on the cell surface and then endocytosis occurred, and the mixture was mixed by pipetting. After a total of 4 hours of incubation, the liquid in each well was transferred to a 5 mL flow tube, and the cells were washed twice with 1×PBS (centrifuged at 400×g for 5 minutes at room temperature), the supernatant was removed, and the cell pellet was resuspended in 300 μL 1×PBS. The cells were kept on ice and protected from light until they were collected on the machine.
[0109] like Fig. 9 As shown, the degranulation ratio of CD107a of T cells under THY culture conditions was 18.9%, which was much higher than the CD107a degranulation level of the control group (5.08%). Therefore, T cells cultured with THY supernatant of newborn calf thymus have stronger killing activity.
[0110] Example 10: Calf thymus supernatant THY promotes T cell perforin secretion
[0111] After the expansion of cytotoxic T cells, the effective killing of target cells depends on the mutual contact between T cells and target cells, and the secretion of perforin and granzyme B, etc. Perforin can bind to the cell membrane and make holes in the cell membrane, thereby destroying the outer membrane of the target cell, allowing granzyme B to be released into the target cell, and then an enzyme-linked reaction occurs to induce apoptosis of the target cell.
[0112] In this example, the concentration of NALM6 cells was adjusted to 10 per ml. 6 The T cell concentration of the experimental group and the control group (wherein, the culture conditions of the experimental group and the control group refer to the above Examples 3 and 4) was adjusted to 5×10 per ml. 6 cells to obtain an effector-target ratio (E:T) of 5:1. According to the two-group setting, it was added to a 96-well U-shaped plate, and 10ng / mL IL7 / IL15 was added to both the control group and the experimental group. The 96-well plate was placed in a cell culture incubator and incubated overnight. After the incubation, the cell supernatant was collected and centrifuged at 300g for 5min, and the supernatant was aspirated. The Human Perforin ELISA Kit (PRF1) (#ab46046; ABCAM) was used to determine the perforin content according to the kit instructions, and the statistics were made and graphed.
[0113] Fig.10 The results showed that after co-culturing T cells from two sources (CD3+T cells isolated from umbilical cord blood and CD3+T cells from peripheral blood, i.e., UBMCT (UBT) and PBMCT (PBT)) cultured in THY with tumor cells, more perforin secretion (>1500pg / ml) could be detected in the culture medium supernatant in both experimental groups compared with the control group.
[0114] Example 11: T cells expanded by calf thymus supernatant THY prolong the survival of mice
[0115] In order to verify whether the T cells expanded by newborn calf thymus supernatant THY injected into mice have the same tumor killing effect, such as Fig.11 As shown in A, this embodiment uses two batches of animal models:
[0116] A batch of mice was used 3X10 5 NALM6-luc tracer tumor cells (#CL-0701; Procell) were injected into immunodeficient mice via the tail vein. After 48 hours, immunodeficient mice with hematologic tumor models were obtained. This group of mice had 12 mice, which were used for subsequent PBMCT (T cells isolated from peripheral blood) cell therapy experiments. The 12 mice obtained by the treatment were divided into three groups: (1) a non-treatment group that was not treated with any cell therapy but only injected with tumor cells, such as Fig.11As shown in yellow in the B line graph; (2) The therapeutic effect of PBMCT cells obtained under PBS culture conditions, such as Fig.11 As shown in the green line in the line graph B; (3) The therapeutic effect of PBMCT cells obtained under THY culture conditions, such as Fig.11 B is shown in red line in line chart.
[0117] Another group of mice were treated with 5X10 5 Number of tumor cells / mouse NALM6-luc tracer tumor cells were injected into immunodeficient mice via tail vein, and 48 hours later, immunodeficient mice with hematologic tumor models were obtained. This group of mice had 7 mice, which were used for subsequent UBMCT (T cells separated from umbilical cord blood) cell therapy experiments; wherein, the 7 mice obtained by the treatment were divided into three groups: (1) a non-treatment group that was not treated with any cell therapy and was only injected with tumor cells, such as Fig.11 C is shown in yellow in the line graph. (2) The therapeutic effect of UBMCT cells obtained under PBS culture conditions, such as Fig.11 C is shown by the green line in the line graph. (3) The therapeutic effect of UBMCT cells obtained under THY culture conditions, such as Fig.11 C is shown in red in the line chart.
[0118] The immunodeficient mice used in this example were huHSC-NCG mice from Guangdong Yaokang Co., Ltd. After the model was successfully established, the survival rate and mortality rate of the mice were recorded on Day 0, Day 7, Day 14, Day 21, Day 28, Day 35, and Day 42, and the survival curve was plotted.
[0119] like Fig.11 As shown, the PBMCT group of mice derived from peripheral blood cultured with the supernatant of newborn calf thymus THY significantly prolonged the survival period of mice compared with the PBS control group (the PBMCT and UBMCT derived from peripheral blood cultured in the THY and PBS control groups are shown in Example 4) (11B): the mice in the untreated group died within four weeks, the longest growth period of the mice in the PBS treatment group was 30 days, and the longest growth period of the mice in the THY group was extended to 38 days after cell therapy. The UBMCT group of mice derived from umbilical cord blood cultured with the supernatant of newborn calf thymus THY also showed a longer survival period compared with the PBS control group (11C): the mice in the untreated group died within three weeks, the longest growth period of the mice in the PBS treatment group was 46 days, and the longest growth period of the mice in the THY group was extended to 52 days after cell therapy.
[0120] Example 12: T cells expanded by calf thymus supernatant THY slow down tumor progression
[0121] This example studies the slowing down of tumor progression by THY-expanded T cells. Two animal models were used: one group of mice was treated with 3×10 5 Number of tumor cells / mouse NALM6-luc tracer tumor cells were injected into immunodeficient mice via tail vein. After 48 hours, immunodeficient mice with hematologic tumor models were obtained. This group of mice had 12 mice and was used for subsequent PBMCT cell therapy experiments. Another group of mice was treated with 5X10 5 The number of tumor cells / NALM6-luc tracer tumor cells were injected into immunodeficient mice through the tail vein, and 48 hours later, immunodeficient mice with hematologic tumor models were obtained. The number of mice in this group was 7, which were used for subsequent UBMCT cell therapy experiments. The experimental process in this embodiment is the same as that in Example 11. The immunodeficient mice selected in this embodiment are huHSC-NCG mice from Guangdong Yaokang Company. After the modeling was successful, photos were taken and recorded using the multi-mode animal in vivo imager AniViewl00Pro on Day7, Day14, Day21, Day28, and Day39.
[0122] like Fig.12 As shown, the AniView100 multi-mode animal in vivo imaging system was used to record the tracer tumor cells NALM6-Luc injected into the tail vein of mice. The strength of the tumor signal was used to represent the size of the tumor. It can be seen that in the newborn calf thymus supernatant THY experimental group, both peripheral blood-derived T cells ( Fig.12 A) or T cells from umbilical cord blood ( Fig.12 B) The time of capturing tumor cell signals was later than that of the control group, and the tumor signals of the control group mice were stronger than those of the THY group at the same time point. This shows that T cells treated with the THY experimental group of newborn calf thymus supernatant have a certain effect on delaying the development of tumors.
[0123] Example 13: Effect of Calf Thymus Supernatant THY on the Number of Hematopoietic Stem Cells Expanded in Vitro
[0124] Hematopoietic stem cells are the progenitor cells of various immune cells, and have the ability to self-renew, multidirectionally differentiate and home. Hematopoietic stem cell transplantation is used to treat diseases such as leukemia and immune system abnormalities.
[0125] In this example, the effect of using the above-mentioned newborn calf thymus supernatant THY on the in vitro expansion of human hematopoietic stem cells HSC (CD34+ cells) was verified. IMDM was supplemented with 10% BIT serum substitute as the basal culture medium for hematopoietic stem cells (HSC), and three growth factors necessary for maintaining stem cell proliferation were added (10ng / mL SCF, 100ng / mL TPO, 100ng / mL FILT3). After 3 days of this basal culture, the 10% THY supplement was added to the basal culture medium and the three cytokines as the experimental group to treat human umbilical cord blood-derived CD34+ hematopoietic stem cells and cultured for 14 days. 10% PBS (as control group 1) and 10% FBS (#10091148; Gibco TM ) (as control group 2). The human umbilical cord blood-derived CD34+ hematopoietic stem cells can be obtained by conventional methods in the prior art (for example, see CN114058584A) and enriched using CD34 microbeads magnetic beads (#130-046-702; Miltenyi) according to the reagent instructions. Fig.13 As shown, it shows that after culturing HSC with calf thymus supernatant THY for 14 days, the cell morphology was observed under a microscope; the number of cells was counted using a CountStar cell counter and analyzed graphically. The results showed that calf thymus supernatant THY can greatly increase the total number of hematopoietic stem cell populations in vitro compared to control group 1 (PBS) and control group 2 (FBS).
[0126] Example 14: Effect of Calf Thymus Supernatant THY on Colony-Forming Ability of Hematopoietic Stem Cells
[0127] At present, the in vitro cloning experiments used to detect hematopoietic stem cells and early progenitor cells are mainly verified by CFU colony formation experiments. CFU experiments are currently the gold standard for in vitro detection of hematopoietic stem cell functions. By simulating the hematopoietic environment and hematopoietic process in vivo, the proliferation and differentiation of hematopoietic stem cells can be observed in vitro, thereby determining whether they have the ability to produce hematopoietic progenitor cells and differentiate into multiple hematopoietic cell lineages, thereby indirectly reflecting the existence of hematopoietic stem cells.
[0128] In this example, the THY extract obtained in Example 1 was used as an additive component of the hematopoietic stem cell (HSC) culture medium to obtain HSCs under three culture conditions: control group 1, basal culture medium StemSpan TM SFEM (#09600; Stemcell Technologies) + 10% PBS; control group 2, basal medium StemSpan TMSFEM (#09600; Stemcell Technologies) + 10% FBS; and experimental group, StemSpan TM SFEM + 10% THY. The HSC cells obtained under the three culture conditions were subjected to CFU colony formation experiments to compare their stem cell stemness. The CFU experiment used methylcellulose semi-solid medium MethoCult TM (#H4330; Stemcell Technologies) as the differentiation medium culture condition. Hematopoietic stem cells cultured under two different conditions will proliferate and differentiate during the culture period to generate mature blood cell colonies. The function and quality of hematopoietic stem cells are identified and analyzed based on the number and type of colonies. CFU colonies are generally divided into: erythroid colony forming units (CFU-E), erythroid colony forming units (BFU-E), granulocyte colony forming units (CFU-G), macrophage colony forming units (CFU-M), granulocyte / macrophage forming units (CFU-GM) and mixed cell line colony forming units (CFU-GEMM).
[0129] Fig.14 The results showed that HSCs obtained under the culture conditions of newborn calf thymus supernatant THY could form more CFU-G, BFU-E, CFU-GEMM, etc. in the CFU formation experiment compared with control group 1 (HSCs obtained under PBS culture conditions) and control group 2 (HSCs obtained under FBS culture conditions). The results show that newborn calf thymus supernatant THY expands a larger number of hematopoietic stem cells with differentiation potential.
[0130] Example 15 Effect of Calf Thymus Supernatant THY on T Cell Proliferation
[0131] Furthermore, in order to verify the excellent effect of the thymus supernatant THY obtained in the present invention, the thymus supernatant THY of the present invention was also compared with thymopentin, thymosin α, and thymosin β4 of thymus extract in the prior art to compare their effects on T cell proliferation.
[0132] The control group "PBS" culture medium composition was ImmunoCult-XF culture medium (#10981; STEMCELL Technology), 10 ng / mL IL7 / IL15, and 10% PBS buffer by volume. Dynabeads were added to this culture medium every three days. TMHuman T-Activator CD3 / CD28 magnetic beads (#11132D; Thermo Fisher) were used as T cell activators. The culture medium composition of experimental group 1 "THY" was based on the culture medium of the control group, in which PBS was replaced, and 2 mg / mL of the above-mentioned newborn calf thymus supernatant THY was added; the culture medium of experimental group 2 "TP5" was based on the culture medium of the control group, in which PBS was replaced, and 1 mg / mL TP5 (thymic pentapeptide; #T2598; TargetMol) was added; the culture medium of experimental group 3 "Tα1" was based on the culture medium of the control group, in which PBS was replaced, and 0.1 mg / mL Tα1, also known as thymic alpha 1 (Thymosinα1; #TP1029; TargetMol) was added; the culture medium of experimental group 4 "Tβ4" was based on the culture medium of the control group, in which PBS was replaced, and 0.1 mg / mL Tβ4 (Thymosinβ4; #TP2319; TargetMol) was added; the action concentrations of the three factors thymic pentapeptide, thymic peptide α, and thymic peptide β4 were determined by reference to the instructions of the reagent company and the working concentrations determined in the published literature by the users of the relevant products. Peripheral blood-derived T cells were cultured in the above five culture medium modes for 14 days, and the total number of cells was counted and recorded using a countstar cell analyzer. The cell expansion multiples were analyzed and plotted. ** represents a p-value less than 0.01.
[0133] like Fig.15 As shown, it can be seen that Tα1 does not affect the in vitro expansion of T cells, but TP5 and Tβ4 have an inhibitory effect on T cell expansion. THY in the present invention has a stronger expansion effect on T cells than thymopentin, thymosin alpha-sin and thymosin β4 in the prior art.
[0134] The specific embodiments described above further illustrate the objectives, technical solutions and beneficial effects of the present invention in detail. It should be understood that the above description is only a specific embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the scope of protection of the present invention.
Claims
1. A method for culturing or expanding immune cells or progenitor cells thereof in vitro, comprising adding an extracellular extract of thymus tissue to a cell culture medium.
2. The method according to claim 1, wherein: The immune cells or their progenitor cells include T cells, B cells, NK cells, NKT cells, macrophages, TIL cells, CIK cells, TCR-T cells and other tumor-killing cells, and hematopoietic stem cells.
3. The method according to claim 1 or 2, wherein: The thymus tissue is obtained from a mammal, preferably a newborn mammal; optionally, the mammal comprises cattle, sheep, horses, pigs, preferably cattle.
4. The method according to claim 1 or 2, wherein: The cell culture medium further comprises IL7 and IL15; preferably, the concentrations of IL7 and IL15 are 5-15 ng / ml, more preferably 8-12 ng / ml, respectively; Preferably, the basal medium of the cell culture medium is 1640 medium, 1640+β-ME medium, αMEM medium, Lonza X-vivo15 medium or ImmunoCult-XF medium; preferably ImmunoCult-XF medium.
5. The method according to claim 1 or 2, wherein: The cell culture medium further comprises 5-15 ng / ml SCF, 80-120 ng / ml TPO, and 80-120 ng / ml FILT3; preferably, the basal culture medium of the cell culture medium is IMDM culture medium.
6. An immune cell or a progenitor cell thereof obtained according to the method of any one of claims 1 to 5.
7. A cell culture medium comprising an extracellular extract of thymus tissue; preferably, the content of the extracellular extract of thymus tissue is 5%-20% by volume.
8. The cell culture medium according to claim 7, further comprising IL7 and IL15; preferably, the concentrations of IL7 and IL15 are 5-15 ng / ml, more preferably 8-12 ng / ml, respectively; Preferably, the basal medium of the cell culture medium is 1640 medium, 1640+β-ME medium, αMEM medium, Lonza X-vivo15 medium or ImmunoCult-XF medium; preferably ImmunoCult-XF medium.
9. The cell culture medium according to claim 7, further comprising 5-15 ng / ml SCF, 80-120 ng / ml TPO, 80-120 ng / ml FILT3; preferably, the basal medium of the cell culture medium is IMDM medium.
10. Use of an extracellular extract of thymus tissue or a cell culture medium according to any one of claims 7 to 9 in culturing or expanding immune cells or progenitor cells thereof in vitro.
11. A method for preparing an extracellular extract of thymus tissue, comprising adding a buffer to the thymus tissue to dissolve the extracellular substances of the thymus tissue in the buffer, and collecting the supernatant by centrifugation.
12. The preparation method according to claim 11, wherein The centrifugation comprises first low-temperature low-speed centrifugation and then low-temperature high-speed centrifugation; Optionally, the low-temperature low-speed centrifugation is 600-4000 rpm, preferably 800-3000 rpm, at 2-10°C, preferably 2-8°C, more preferably 4-6°C, for 5-15 minutes; optionally, the low-temperature high-speed centrifugation is 6000-12000 rpm, at 2-10°C, preferably 2-8°C, more preferably 4-6°C, for 20-40 minutes.
13. A preparation comprising the immune cell or progenitor cell thereof according to claim 6; optionally, the preparation further comprises a pharmaceutically acceptable excipient.
14. Use of the immune cell or progenitor cell thereof according to claim 6 or the preparation according to claim 13 in the preparation of a medicament for treating a tumor; optionally, the tumor comprises a solid tumor or a non-solid tumor.
Citation Information
Patent Citations
Milk containing thymus polypeptide extraction and preparation method thereof
CN101167497A
Culture method for in-vitro induction of NK cell after recovery of cryopreserved human PBMC
CN111718899A
Bone marrow supernate and application thereof in cell culture
CN115125192A
Preparation of a pharmaceutically active solution from thymus gland
GB1023849A
Thymic epithelial cells with progenitor capacity
WO2003105874A1
